Definium Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 69.23K shares, a 65.90% decline year-over-year.
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 163.35K shares, a 205.09% increase year-over-year.
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 41.13K shares, a 255.06% increase year-over-year.
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 17.42K shares, a 69.17% decline year-over-year.
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 315.09K shares, a 45.89% increase from fiscal 2024.
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 215.98K shares, a 1519.88% increase from fiscal 2023.
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 13.33K shares, a 65.17% decline from fiscal 2022.
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 38.28K shares, a 99.68% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 69.23K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 291.13K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 163.35K shares 10-Q · filed 2026-05-07 | 424.90K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 41.13K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 315.09K shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 17.42K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 285.55K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 203.01K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | 324.63K shares derived: sum of 4 quarters · filed 2025-07-31 |
| 2025-03-31 | 53.54K shares 10-Q · filed 2025-05-08 | 150.62K shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 11.58K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 215.98K shares 10-K · filed 2025-03-06 |
| 2024-09-30 | 56.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 204.40K shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 29.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | |
| 2024-03-31 | 118.90K shares 10-Q · filed 2024-05-08 | |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | 13.33K shares 10-K · filed 2024-02-28 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | 38.28K shares 10-K · filed 2023-03-09 |
| 2022-09-30 | -404.43K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | |
| 2022-06-30 | 125.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | |
| 2022-03-31 | 317.71K shares 10-Q · filed 2022-05-16 | |
| 2021-12-31 | 12.06M shares 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cronos Group Inc. (CRON) | $1.223B | ||
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B |